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Inflammatory role of dendritic cells 
in Amyotrophic Lateral Sclerosis 
revealed by an analysis of patients’ 
peripheral blood
Michela Rusconi1, Francesca Gerardi2, William Santus1, Andrea Lizio2, Valeria Ada Sansone2,4, 
Christian Lunetta2, Ivan Zanoni1,3 & Francesca Granucci1
Chronic inflammation is one of the causes of neurodegeneration in Amyotrophic lateral sclerosis (ALS). 
Here we examined whether circulating dendritic cells (DCs) can contribute to disease progression. We 
found ALS patients show a significant reduction in the number of circulating DCs. Also, patients’ DCs 
present an increased expression of CD62L and a tendency to overexpress CCR2 compared with healthy 
donors. Moreover, DCs derived from a subpopulation of ALS patients produced higher levels of IL-8 and 
CCL-2 upon lipopolysaccharide (LPS)-stimulation. Finally, we found a significant inverse correlation 
between the time from onset of the pathology to its diagnosis and the levels of IL-6 secretion induced 
by LPS. Our data support the hypothesis, in a subpopulation of patients, DCs recruited at the diseased 
tissue produce high levels of CCL-2 and IL-8 and contribute to the inflammatory process promoting the 
recruitment of other inflammatory cells. An increased efficiency of IL-6 production may accelerate only 
the initial phases of disease progression. Blood DC analysis can be used to identify ALS patients with an 
altered course of inflammatory cell recruitment at the diseased central nervous system (CNS). The high 
levels of CD62L expression suggests this molecule could be a target for treatment of CNS inflammation.
Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease, also known as Lou Gehrig’s disease, 
described for the first time by Jean Martin Charcot in 1800. It affects both upper (UMN) and lower motor neurons 
(LMNs) in the cortex, brainstem and spinal cord.
The name of the pathology resumes all the major features of the disease. “Amyotrophic” refers to muscular 
atrophy, and “lateral sclerosis” pertains to the scarring in the lateral aspect of the spinal cord1. ALS is a clinically 
heterogeneous disease characterized by muscles wasting, weakness, paralysis, swallowing impairment and res-
piratory failure that may occur in month or in years. These clinical features can also be accompanied or preceded 
by frontotemporal dementia2. Approximately 10% of ALS patients are familial and in the 20% of these cases the 
disease is caused by mutations in the gene encoding superoxide dismutase 1 (SOD1)3, 4. The cause of sporadic ALS 
(sALS) is incompletely defined and there is a consensus that pathogenesis is probably multifactorial.
Increasing evidence support the importance of chronic inflammation to drive neurodegeneration in ALS5. 
Spinal cord infiltration by peripheral proinflammatory monocytes, dendritic cells (DCs) and T cells has been 
found in patients and animal models6. Both CD4+ and CD8+ T lymphocytes infiltrates the brains of ALS patients 
and -by interacting with glial cells- could play a role in motor neuron degeneration. Also, DNA microarray analy-
sis on postmortem spinal cord tissue obtained from individuals with sALS has revealed changes in the expression 
of genes involved in the inflammatory process7, 8. Similarly, autopsy of sALS patients and analyses of SOD1 trans-
genic mice have confirmed the idea that both innate and adaptive immunity are involved in the neurodegenera-
tive process9–11.
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Inflammation in ALS is not limited to the Central Nervous System (CNS) but is also present at the systemic 
level. This includes: increased numbers of circulating activated lymphocytes, higher levels of MHC class II expres-
sion on monocytes and higher levels of inflammatory serum cytokines. Patients with a pathology that rapidly 
progress also show low numbers of blood regulatory T cell (Tregs)12 and increased levels of lipopolysaccharide 
(LPS) in the plasma13. High endotoxin levels may contribute to chronic low-grade inflammation as manifested in 
chronic disease such as Parkinson’s disease and atherosclerosis14. Among the cells that respond to LPS, myeloid 
DCs are central players of the immune response. DCs decide of the activation of T cells through the presentation 
of the peptide–MHC complex (signal 1), the expression of costimulatory molecules (signal 2), and the production 
of cytokines (signal 3) activation15. The type of immune response induced by DCs strongly depends on the quality 
of the signals DC encounter16. In human peripheral blood, two main populations of DCs can be distinguished: 
CD11chigh myeloid DCs that are strongly activated by LPS, and CD11clow plasmacytoid DCs. These DCs express 
distinct receptors for inflammatory stimuli and respond to different pathogenic stimuli, suggesting that each 
subset has a specialized function in directing T cells responses.
Because of their unique capacity to shape immune responses, DCs play important roles in the pathogenesis 
of several inflammatory diseases including neuroinflammatory disorders17. Studies on human DCs demonstrate 
that in the peripheral blood of patients with progressive neurodegeneration, these cells are functionally altered 
and more prone to skew T cell responses towards a proinflammatory phenotype18. In ALS, there is evidence that a 
transition from a neuroprotective Treg infiltrate to a deleterious Th1 response characterizes the increase in disease 
severity19.
Although DCs play a major role in shaping immune responses, their phenotype and functional features in 
peripheral blood of ALS patients have not been investigated. Understanding the possible alteration in the func-
tionality of DCs in ALS patients compared to healthy subjects or patients affected by other neurodegenerative 
disorders could therefore represent an important step toward the definition of the inflammatory process that 
contributes to the progression of the disease. This could have important implications to define the prognosis and 
to select ALS patients potentially more responsive to therapeutic strategies for modifying the inflammatory state 
to restore the normal immune conditions.
Here we have investigated the functionality of peripheral blood myeloid DCs in ALS patients and correlated it 
with patients’ clinical state. A large cohort of ALS patients has been enrolled in the present study. Ex vivo analyses 
of the frequency and expression of costimulatory, MHC and migratory molecules of the major myeloid DC subset 
have been performed and the capacity of purified DCs to produce cytokines has been investigated in vitro.
This study provides a detailed picture of the functional state of blood DCs in ALS patients.
Results
Patients enrolled in the study. ALS patients enrolled in the study showed the presence of combined UMN 
and LMN involvement in at least one body region, and were classified with definite or probable diagnosis accord-
ing to the revised El Escorial criteria20. We studied in total 72 patients, 20 for flow cytometry analyses and 52 for 
cytokine expression, all with sporadic ALS. Supplementary Tables 1–6 resume the characteristics of ALS patients 
and controls enrolled in the study.
The expression of the disease was assessed based on the ALS-Functional Rating Scale-Revised (ALS-FRS-R) 
and the definition was as follows: severe, with ALS-FRS-R score lower than 28; mild, with ALS-FRS-R score 
ranged from 29 to 43; and slight, with ALS-FRS-R score upper than 44. Rapidity of disease progression was 
assessed using the ratio between the score lost on the ALS-FRS-R and the disease duration: Progression 
index = (48 − ALS-FRS-R score)/duration in months.
Healthy Donors (n = 37, HD) and non-ALS Neurological Patients (n = 25, other neurological diseases, OND) 
stratified for age and sex were also enrolled as control.
ALS patients show decreased numbers of circulating DCs that express higher levels of CD62L 
compared to healthy controls. The frequency of myeloid DCs was analyzed in peripheral blood of ALS 
patients and healthy donors (HD). Characteristics of patients and HD used for this analysis are resumed in 
Supplementary Tables 1 and 2. In the blood, CD1chigh cells represent the major subset of myeloid DCs21. High 
amounts of CD1c are expressed also by a subset of small resting B cells, therefore we identified myeloid DCs as 
CD1chighCD19−. As shown in Fig. 1a, ALS patients had significantly less circulating DCs than HD.
Next, we examined the expression of activation markers (MHC and the costimulatory molecules CD80, 
CD86, CD40), and molecules involved in DC migration (CD62L, CCR5, CCR7 and CCR2). No differences were 
observed in the expression of MHC and costimulatory molecules, as well as the CCR5 and CCR7 chemochines 
(Fig. 1a,d–l). An increased trend of expression was, instead, observed for CCR2 and a significantly higher CD62L 
expression was measured on DCs from ALS patients compared to HD (Fig. 1b,c).
CD62L is a cell adhesion molecule required for the recruitment of the innate and adaptive cells into inflamed 
lymph nodes and tissues22. Also, CCR2 and its ligand CCL-2 are molecules extensively studied for their involve-
ment in CNS inflammatory diseases including, multiple sclerosis, Alzheimer’s disease and ischemic stroke23. In 
these previously published studies, CCR2 appears as one of the major molecules required for inflammatory cell 
homing to the CNS. This suggests that also in some ALS patients CCR2 could be involved in DC recruitment at 
the diseased tissue.
The decrease of circulating DC numbers and the increased CD62L expression suggests DCs are actively 
recruited at the inflamed CNS in ALS patients.
Peripheral blood DCs from a sub-population of ALS patients produce higher amounts of IL-8 
and CCL-2 compared to controls. Since we observed the upregulation of receptors involved in DC migra-
tion, we, next, tested whether the capacity of patients’ DCs to produce chemokines involved in inflammatory cell 
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recruitment was also altered. We therefore analyzed the production of interleukin (IL)-8 (important for neutro-
phil recruitment), and CCL-2 (a key chemokine for the recruitment of inflammatory cells at the CNS). CD1chigh 
DCs were purified from peripheral blood (Fig. 2a) and cultured in the presence or not of LPS. Purified CD1chigh 
contained two DC sub-populations recently classified as DC2 (CD1chighCD14−) and DC3 (CD1chighCD14+)21. 
DC3 were previously erroneously considered monocytes. DC3 differ from monocytes because they express high 
levels of CD1c, while monocyte express intermediate levels (Fig. 2b)24. LPS was chosen as a prototypic inflamma-
tory agent and because of the increased levels of this ligand in the blood of ALS patients. The amount of cytokine 
released in the supernatant was then measured 24 hours later. Characteristics of ALS patients, HD and OND 
patients used for this analysis are resumed in Supplementary Tables 3–5.
We first analyzed the total unselected ALS population and we did not observe a significant difference in 
chemokine production among ALS patients, HD and OND (Fig. 2c,d). Nevertheless, we observed that ALS 
patients clustered in three distinct sub-populations with a sub-population (Supplementary Table 6), positioned 
in the fourth quartile, showing an unusual very high LPS-induced production of IL-8 (Fig. 2c). We focused our 
analysis on these patients and we found they also showed a significant higher efficiency of CCL-2 production 
compared to controls (Fig. 2d). This behavior was specific for CCL-2, since all the other cytokines tested did not 
show this segregated distribution (Supplementary Figure 1).
These results suggest that in a subpopulation of ALS patients, DCs can contribute to the inflammatory process 
by producing inflammatory chemokines, such as CCL-2 and IL-8, in the inflamed lymph nodes and CNS, and 
contributing to the recruitment of inflammatory cells, i. e. T cells.
We then investigated whether there was a correlation between the efficiency of IL-8 and CCL-2 production 
by ALS patients’ DCs before and after LPS exposure and several clinical disease parameters, including: i) site of 
onset, ii) non-invasive mechanic ventilation (NIV), iii) radiological inserted gastrostomy/percutaneous endo-
scopic gastrostomy (RIG/PEG), iv) ALS-Functional Rating Scale-Revised (alsfrs-r), v) disease progression, vi) 
alsfrs-r bulbar, vii) alsfrs-r respiratory, viii) alsfrs-s spinal, ix) time from onset to diagnosis, x) time from onset to 
evaluation and, xi) time from diagnosis to evaluation. The correlations between disease parameters and cytokine 
production were analyzed with the Spearman test in univariate models (Supplementary Tables 7 and 8). The 
correlations with a p-value < 0,2 were analyzed again in a multivariate model adjusting for age and sex. We were 
not able to identify any correlation (data not shown), which is presumably due to the high disease heterogeneity. 
Nevertheless, high levels of CCL-2 have been shown in the spinal cord of SOD mice25, a mouse model of a sub-
class of ALS disease, and in some ALS patients26, 27. Therefore, the altered efficiency of chemokine production by 
DCs could impact on neuroinflammation in a subpopulation of ALS patients that can be identified by peripheral 
blood analysis.
Figure 1. Phenotypic analysis of peripheral blood DCs in ALS patients compared to HD. (a) Box plots of 
absolute numbers of CD1c+CD19− DCs in the peripheral blood of ALS patients (ALS, n = 20) and HD (n = 10). 
(b–l) Box plots of the Mean Fluoresce Intensity (MFI) of the indicated molecules in ALS patients compared to 
HD. *P < 0.05; **P < 0.01.
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Peripheral blood DCs from ALS patients do not show any difference in the production IL-12p40, 
TNF-α, IL-1β, IL-6 and IL-10 compared to controls. We then investigated whether DCs in ALS patients 
contribute to neuroinflammation also via an altered production of classical inflammatory or anti-inflammatory 
cytokines. CD1c+ DCs were tested for their capacity to produce IL-12p40, TNF-α, IL-1β, IL-6 and IL-10 sponta-
neously or after LPS challenge.
No significant differences were observed in the spontaneous or LPS induced release of IL-12p40, TNF-α, 
IL-1β, IL-6 and IL-10 among ALS patients, HD and OND (Fig. 3a–e). Also, analyzing the selected population 
expressing high amounts of IL-8 and CCL-2 no significant alteration in the expression of these cytokines was 
found. We then investigated whether there was a correlation between the amounts of single cytokine produced by 
ALS DCs before and after LPS exposure and the disease parameters as described above. Although many parame-
ter were statistically significant in the univariate analysis (Supplementary Tables 9–12), no significant correlations 
were found with the multivariate analysis (data not shown) except a significant inverse correlation between the 
time from onset to diagnosis and the ΔIL6 levels (the amount of IL6 produced after LPS stimulation minus the 
amount of IL6 spontaneously produced) (Fig. 3f and Supplementary Tables 12 and 13).
A longitudinal assay of cytokine production by peripheral blood DCs was performed to investigate possible 
variations during disease progression. The efficiency of cytokine production remained relatively constant over 
time (Fig. 4).
Collectively these results suggested DC-derived IL-6 may have a potential inflammatory role in the CNS or in 
the inflamed lymph node during the initial disease phases. Diversely, DCs do not contribute to the inflammatory 
process in ALS patients by over-producing the classical inflammatory cytokines or down-modulating the produc-
tion of anti-inflammatory cytokines.
Discussion
Several published data highlight the contribution of chronic neuroinflammation in the degenerative process 
of ALS. Inflammatory T cells infiltrate the CNS of ALS patients and by interacting with glial cells contribute 
to motor neuron degeneration28. To differentiate into inflammatory cells and to acquire the ability to infiltrate 
diseased tissues, T cells need to interact with professional antigen presenting cells (APCs). Among APCs, mye-
loid DCs are the most efficient cells in priming T cells and skewing their responses toward an inflammatory or 
Figure 2. Amounts of spontaneous or LPS-induced chemokine production by DCs purified from peripheral 
blood of ALS patients (n = 52), HD (n = 36) or OND (n = 25). (a) Cytofluorimetric analysis of sorted DCs. The 
percentages of CD1chigh cells and of the T, B and NK cell contaminants are shown. (b) CD1c expression levels 
shown by CD14+ DCs and CD14+ monocytes. Notice that the two cell types can be distinguished based on the 
levels of CD1c expression. (c) Scatter plots of the amounts of IL-8 and CCL-2 produced by DCs from ALS, HD 
and ODN 24 h after in vitro culture in the presence or absence of LPS. Black dots in LPS-induced IL-8 plots 
(second to the left panel) are the selected patients with high efficiency of IL-8 production, red dots represent 
patients with low IL-8 production. (d) Efficiency of LPS-induced CCL-2 production by DCs from the selected 
high IL-8 producers. Each dot represents a patient. **P < 0.01.
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anti-inflammatory phenotype29. For this reason, DCs are often deregulated in inflammatory conditions, including 
neurodegenerative diseases30.
The identification of any possible alteration in the functionality of DCs in ALS patients may help defining 
the origin of inflammation that is important to drive neurodegeneration. Here, we have investigated the phe-
notype and functionality of circulating DCs in a large cohort of ALS patients. Ex vivo analyses of the frequency, 
the expression of costimulatory, MHC and migratory molecules of the CD1c+ DC subset as well as their abil-
ity to produce inflammatory and anti-inflammatory cytokines spontaneously and in response to LPS has been 
investigated.
We found ALS patients have a significant decrease in the number of circulating DCs. Also, these DCs present 
an increased expression of CD62L compared with healthy donors. We identified a subpopulation of ALS patients 
with higher LPS-induced IL-8 and CCL-2 production. Ultimately, we identified a significant inverse correlation 
between the time from onset to diagnosis and the levels of IL-6 secretion after LPS challenge.
The L-selectin CD62L is a homing leukocytes’ receptor for entering secondary lymphoid tissues, via high 
endothelial venules, or inflamed tissues22. The prediction of an increased recruitment of circulating DCs to the 
CNS is also supported by the decrease of peripheral blood DC numbers observed in ALS patients compared to 
healthy donors.
Our data support published results showing mRNAs coding mature and immature DC markers in the spinal 
cord of ALS patients, and the presence of CD1a+CD83+ perivascular cells in the degenerating corticospinal tract 
of ALS patients9.
The finding of the upregulation of the levels of CD62L in ALS patients DCs compared to controls is surpris-
ing since a downregulation this molecule has been, instead, described in PBMCs and monocytes in Westerners 
Indians and Japanese patients31, 32.
Downregulation of CD62L and CCR2 by classical monocyte described in literature has been interpreted as a 
dysregulation in the homing capacity of these leukocytes and a patient compensatory response to avoid further 
inflammation at the diseased tissue. Our observation of CD62L upregulation in DCs argues in favor of a pivotal 
inflammatory role of these cells during the course of the disease.
A subpopulation of ALS patients also present an overproduction of IL-8 and CCL-2 in response to LPS. 
CCL2 is a potent chemoattractant expressed mostly by astrocytes, but also by neurons, microglia. CCL-2 attracts 
CCR2/4-expressing leukocytes, including T cells33. According with our results, an increase in CCL-2 expression 
by DCs has been described in mSOD1 mice. The CCL-2 increased expression is seen before any signs of disease 
Figure 3. Amounts of spontaneous or LPS-induced cytokine production by DCs purified from peripheral 
blood of ALS patients (n = 52), HD (n = 36) or OND (n = 25). (a–e) Scatter plots of the amounts of the 
indicated cytokines produced by DCs from ALS, HD and ODN 24 h after in vitro culture in the presence or 
absence of LPS. (f) IL-6 and Time from Onset to Diagnosis correlation. An inverse correlation (p = 0,048 - 
Spearman test) between the time from onset to diagnosis and the ΔIL-6 levels (IL-6 LPS – IL-6 NT) is shown.
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and may indicate the presence of injured cells as early as 15 days of age34. In patients, an increase of CCL-2 
amounts in the cerebrospinal fluid (CSF) and spinal cord of ALS compared with controls has been reported9. Our 
observations suggest DC recruited from peripheral blood can be an additional source of CCL-2 in the CNS of 
ALS patients.
IL-8 is a potent chemotactic signaling factor for recruitment of neutrophils to inflamed tissues. Higher 
amounts of IL-8 have been found in the CSF and serum from ALS patients compared to HD and individuals with 
non-inflammatory diseases, with considerably higher amount in the CSF compared to serum11, 35. A correlation 
with serum IL-8 levels and disease progression has been also described36, 37.
The deregulated IL-8 production by DCs in a subpopulation of ALS patients suggests DCs may represent 
another source of IL-8 in the inflamed CNS in addition to microglial cells. Given the high amounts of IL-8 released 
by DCs from some ALS patients we can predict that also neutrophils efficiently contribute to neuroinflammation.
The CD62L overexpression by peripheral inflammatory DCs could be exploited as a target molecule for dis-
ease treatment. To date there are no authorized clinical treatment for ALS with anti-CD62L drugs. In the clinic, 
the blocking anti-CD62L antibody Natalizumab has been tested in the treatment of relapsing and remitting mul-
tiple sclerosis38 with positive results. A reduction of the annual relapse rate in two clinical trials by 68% has been 
observed39, 40. Considering that Natalizumab could reduce the recruitment at the inflammatory site of all CD62L 
positive leukocytes, a positive prediction on ALS symptom reduction could be envisaged.
In the present work, we have also found an inverse correlation between the time from onset to diagnosis and 
the levels of IL6 secretion induced by LPS. The role of IL-6 signaling in neurological diseases has not been com-
pletely clarified and may vary depending on the disease stages, on the ratio of free IL-6 and sIL-6R or other factors 
specific for each disease41.
The humanized anti-IL-6R antibody tocilizumab inhibits IL6 signaling through both IL-6R and sIL6-R. 
Tocilizumab has shown a favorable long-term effect in patients with rheumatoid arthritis42 and is under study in 
patients with Castleman’s disease, juvenile rheumatoid arthritis and inflammatory bowel disease43.
An in vivo trial of Tocilizumab efficacy in ALS treatment has been recently conducted44. Only patients show-
ing a high proinflammatory profile showed a dramatic downmodulation of their inflammatory state with atten-
uation in the disease progression observed only in a minimal number of patients. The effects were demonstrated 
to be individual and time- and dose dependent45. Our observation of an inverse correlation between the time 
from onset to diagnosis and the levels of IL6 secretion induced by LPS deserves further investigation on a possible 
involvement of IL-6 in promoting neurodegeneration only during the very early disease stages. This may explain 
Figure 4. Longitudinal analysis of cytokine production. Scatter plots of the amounts of the indicated cytokines 
produced by DCs from ALS, HD and ODN 24 h after in vitro culture in the presence or absence of LPS. Three 
time points are shown, the first measure (t0) and the analyses performed 3 months (t3) and 6 months (t6) after 
the first test.
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the difficulties in the interpretation of the anti-IL6R trial results. It is conceivable that an intervention on the 
IL-6-IL6R axis only during the initial symptomatic phases could be of some efficacy.
In conclusion, an analysis of peripheral blood DCs can be useful to identify ALS patients with an altered 
course of inflammatory cell recruitment at the diseased tissue. The high levels of CD62L expression by peripheral 
blood DCs indicate this molecule as a possible new target for in vivo treatment to reduce CNS inflammation.
Material and Methods
Patients’ enrollment. We studied 72 patients with ALS, consecutively recruited from the ALS Centre at 
the NEuroMuscular Omnicentre (NEMO). The diagnosis of ALS was based on a detailed history and physi-
cal examination, and supported by the electrophysiological evaluation. Other causes of disease were excluded 
by appropriate blood tests and neuroimaging. ALS patients showed the presence of combined UMN and LMN 
involvement in at least one body region, and were classified with definite or probable diagnosis according to the 
revised El Escorial criteria20.
All subjects were free of any infection and inflammatory or allergic reaction for at least 2 weeks prior to 
study admittance. Acute phase reactants (ESR, C-reactive protein, alpha 2-globulins) and rheumatoid factor 
were negative at blood tests. All patients were taking over 6 months Riluzole, but no therapy with poten-
tially anti-inflammatory properties was administered at the time of the study. The ALS-Functional Rating 
Scale-Revised (ALS-FRS-R) was used to assess the expression of disease that was rated as follows: severe, 
with ALS-FRS-R score lower than 28; mild, with ALS-FRS-R score ranged from 29 to 43; and slight, with 
ALS-FRS-R score upper than 44. Rapidity of disease progression was assessed using the ratio between the 
score lost on the ALS-FRS-R and the disease duration: Progression index = (48 − ALS-FRS-R score)/duration 
in months.
Healthy Donors (n = 37) and non-ALS Neurological Patients (n = 25) stratified for age and sex were also 
enrolled as control.
Supplementary Tables 1–6 resume the characteristics of ALS patients and controls enrolled in the study.
All methods were carried out in accordance with relevant guidelines and regulations. All experimental pro-
tocols were approved by the Ethics Committees of NEMO and University of Milano-Bicocca. Informed consent 
was obtained from all subjects.
CD1c+ DC purification and culture. Blood samples from ALS patients, were obtained after written 
informed consent. From all subject whole blood was collected by venopuncture in vacutainer tubes containing 
ethylenendiamine tetra-acetic acid (EDTA; Becton Dickinson, Rutheford, NJ).
DC purification was performed from 18 ml of peripheral blood using CD1c (BDCA-1) Dendritic Cells 
Isolation kit purchased from Miltenyi Biotech (purity 90%). Cell contaminants were defined by evaluating the 
presence of B, T, NK cells and monocytes in the purified population. Purified CD1chigh DCs (30.000) were plated 
in RPMI (Euroclone) medium containing g 10% heat-inactivated fetal bovine serum (Gibco, cat. 10270), 100 IU 
of penicillin, 100 µg/ml of streptomycin, 2mM l-glutamine (all from Euroclone) complete medium and cultured 
in the presence or absence of 100 ng/mL LPS for 24 hours in 96 well suspension u-bottom plates. The supernatants 
were than collected for ELISA assays.
Flow cytometry. After red blood cell lysis, single cell suspensions of blood samples (15 ml) from ALS 
patients and healthy donors were pelleted, resuspended with the appropriate amount of antibody in 200 μl of PBS, 
and incubated for 20 min on ice in the dark. Cells were than washed once with 1 ml of PBS and resuspended in a 
final volume of 270 μl of PBS. Finally, 30 μl of Beckman Coulter Flow-Count Fluorospheres have been added to 
the samples to determine absolute cells numbers. Peripheral blood DCs have been gated on CD1chighCD19− cells. 
Monocytes were excluded based on side and forward scatter parameters.
For cytofluorimetric analysis, the antibodies used were as follows: anti-CD1c-PE (L161), anti-CD19-APC 
(HI19), anti-CCR5-alexa700 (HEK/1/85a), anti-HLA DR/DP/DQ-FITC (Tu39), anti-HLA A/B-Pacific 
Blue (W6/32), anti-CCR7-APC,-Cy7 (G04347), anti-CCR2-PECy7 (KO36C2), anti-CD80-FITC (2D10), 
anti-CD86-Pacific Blue (IT2.2), anti-CD62L Alexa700 (DREG-56), anti-CD40-PECy7 (5C3); anti-CD3-PEcy7 
(HIT3a), anti-CD1c-APCcy7 (L161), anti-CD14-PE (HCD14), anti-CD19-FITC (HIB19), anti-CD56-APC 
(NCAM) all from Biolegend. Samples were acquired with a Gallios flow cytometer (Beckman-Culter) and ana-
lyzed with FlowJo (TreeStar) software.
ELISA assay. Concentrations of TNF-α, IL-1β, IL-6, IL-12p40, IL-8, CCL2 and IL-10 in BDCA1+ DC super-
natants were assessed by ELISA kits purchased from R&D Systems.
Antibodies and chemicals. Antibodies for flow cytometry were purchased from Biolegend and TRL4-grade 
smooth LPS (E. coli,O55:B5) was purchased from Enzo Life Sciences.
Statistical Analysis. Medians were compared by Wilcoxon Test or Kruskal-Wallis Tests. Data are expressed 
and plotted as median [Q1-Q3]. Sample sizes for each experimental condition are provided in the figures and the 
respective legends. The correlations between disease parameters and cytokine production were analyzed with the 
Spearman test in univariate models. The correlations with a p-value < 0,2 were analyzed again in a multivariate 
model adjusting for age and sex.
Data availability. Data and associated protocols promptly available to readers.
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